# US 2010/0166792 A1 · Antigenic Polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166792 A1
- Document ID: US20100166792A1
- Status: Published application
- Kind: A1
- Application number: 12/555,626
- Filed: 2009-09-08
- Published: 2010-07-01
- Earliest claimed: 2000-06-20
- Assignees: Biosynexus Incorporated
- Inventors: Simon Foster; Philip McDowell; Kirsty Brummell; Simon Clarke
- Web page: https://patentgrep.com/patent/US20100166792A1

## CPC

- C07K 14/31: from Staphylococcus (G)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 39/02: Antidotes
- C07K 16/12: against material from bacteria
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides.

## Claims

### Claim 1

An immunogenic composition comprising a carrier or adjuvant and at least one isolated polypeptide comprising all or a portion of SEQ ID NO.: 27.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein said isolated polypeptide comprising the amino acid sequence of SEQ ID NO. 27 is a recombinant polypeptide.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, further comprising one or more polypeptides selected from the group consisting of SEQ ID NOs. 14-26 and 28-32.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, further comprising two or more polypeptides selected from the group consisting of SEQ ID NOs. 14-26 and 28-32.

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, further comprising an isolated polypeptide comprising all or a portion of SEQ ID NO. 15.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, further comprising an isolated polypeptide comprising all or a portion of SEQ ID NO. 14.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, further comprising an isolated polypeptide comprising all or a portion of SEQ ID NO. 17.

### Claim 8 (depends on 1)

The immunogenic composition of claim 1, further comprising an isolated polypeptide comprising all or a portion of SEQ ID NO. 28.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1, further comprising an isolated polypeptide comprising all or a portion of SEQ ID NO. 29

### Claim 10 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition is formulated for administration to a subject, wherein said administration is selected from the group consisting of intravenous injection, intramuscular injection, subcutaneous injection and orally.

### Claim 11 (depends on 1)

The immunogenic composition of claim 1, further comprising at least one protein from Staphylococcus aureus.

### Claim 12 (depends on 1)

The immunogenic composition of claim 1, further comprising at least one protein from Staphylococcus epidermidis.

### Claim 13 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition is capable of generating an effective immune response against Staphylococcus aureus.

### Claim 14 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition is capable of generating an effective immune response against Staphylococcus epidermidis.

### Claim 15 (depends on 1)

The immunogenic composition of claim 1, wherein said immunogenic composition is utilized in the treatment of prevention of staphylococcal infection.

### Claim 16

A method of preparing an immune globulin for use in prevention or treatment of staphylococcal infection comprising the step of immunizing a recipient with an immunogenic composition comprising a carrier or adjuvant and at least one isolated polypeptide comprising all or a portion of SEQ ID NO.: 27, and isolating an immune globulin from the recipient.

### Claim 17

A method of inducing an immune response to Staphylococcus aureus in a subject, comprising administering to said subject an immunogenic composition comprising a carrier or adjuvant and at least one isolated polypeptide comprising all or a portion of SEQ ID NO.: 27.
